Last reviewed · How we verify
Originator rituximab - Rituxan ® or MabThera ®
Originator rituximab - Rituxan ® or MabThera ® is a CD20-targeting monoclonal antibody Biologic drug developed by Sandoz. It is currently in Phase 3 development for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system. Used for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.
At a glance
| Generic name | Originator rituximab - Rituxan ® or MabThera ® |
|---|---|
| Sponsor | Sandoz |
| Drug class | CD20-targeting monoclonal antibody |
| Target | CD20 |
| Modality | Biologic |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
Rituximab targets CD20, a surface antigen expressed on B lymphocytes. By binding to CD20, it triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B cell depletion. This mechanism is effective in B-cell malignancies and autoimmune diseases where B cells play a pathogenic role.
Approved indications
- Non-Hodgkin's lymphoma (B-cell)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
Common side effects
- Infusion reactions
- Infections
- Cytopenias (anemia, thrombocytopenia, neutropenia)
- Fatigue
- Fever
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Originator rituximab - Rituxan ® or MabThera ® CI brief — competitive landscape report
- Originator rituximab - Rituxan ® or MabThera ® updates RSS · CI watch RSS
- Sandoz portfolio CI
Frequently asked questions about Originator rituximab - Rituxan ® or MabThera ®
What is Originator rituximab - Rituxan ® or MabThera ®?
How does Originator rituximab - Rituxan ® or MabThera ® work?
What is Originator rituximab - Rituxan ® or MabThera ® used for?
Who makes Originator rituximab - Rituxan ® or MabThera ®?
What drug class is Originator rituximab - Rituxan ® or MabThera ® in?
What development phase is Originator rituximab - Rituxan ® or MabThera ® in?
What are the side effects of Originator rituximab - Rituxan ® or MabThera ®?
What does Originator rituximab - Rituxan ® or MabThera ® target?
Related
- Drug class: All CD20-targeting monoclonal antibody drugs
- Target: All drugs targeting CD20
- Manufacturer: Sandoz — full pipeline
- Therapeutic area: All drugs in Oncology, Immunology
- Indication: Drugs for Non-Hodgkin's lymphoma (B-cell)
- Indication: Drugs for Chronic lymphocytic leukemia (CLL)
- Indication: Drugs for Rheumatoid arthritis
- Compare: Originator rituximab - Rituxan ® or MabThera ® vs similar drugs
- Pricing: Originator rituximab - Rituxan ® or MabThera ® cost, discount & access